This company listing is no longer active
Endo (NDOI) Stock Overview
A specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
NDOI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Endo, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.59 |
| 52 Week High | US$31.40 |
| 52 Week Low | US$19.85 |
| Beta | 0 |
| 1 Month Change | 13.58% |
| 3 Month Change | 10.97% |
| 1 Year Change | -18.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -16.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| NDOI | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.6% | 0.5% | -0.5% |
| 1Y | -18.0% | 26.6% | 16.9% |
Return vs Industry: NDOI underperformed the US Pharmaceuticals industry which returned -7.7% over the past year.
Return vs Market: NDOI underperformed the US Market which returned 15.7% over the past year.
Price Volatility
| NDOI volatility | |
|---|---|
| NDOI Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: NDOI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NDOI's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 3,116 | Scott Hirsch | www.endo.com |
Endo, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally. The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology. It is involved in the developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty.
Endo, Inc. Fundamentals Summary
| NDOI fundamental statistics | |
|---|---|
| Market cap | US$1.76b |
| Earnings (TTM) | US$5.48b |
| Revenue (TTM) | US$1.73b |
Is NDOI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NDOI income statement (TTM) | |
|---|---|
| Revenue | US$1.73b |
| Cost of Revenue | US$1.46b |
| Gross Profit | US$274.83m |
| Other Expenses | -US$5.21b |
| Earnings | US$5.48b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 06, 2025
| Earnings per share (EPS) | 71.87 |
| Gross Margin | 15.85% |
| Net Profit Margin | 316.41% |
| Debt/Equity Ratio | 216.3% |
How did NDOI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/31 10:14 |
| End of Day Share Price | 2025/07/31 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Endo, Inc. is covered by 32 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Gary Nachman | BMO Capital Markets Equity Research |
| Sumant Satchidanand Kulkarni | BofA Global Research |